Docket No.: 3687.1000-004

@PFDettop\::ODMA/MHODMA/HBSR05;iManage;516362;1

DMH/MKM/jiw Decomber E 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Lynn A. Doucette-Stamm and David Bush

Application No.:

10/617,320

Group:

1631

Filed:

July 10, 2003

Examiner:

Zhou, Shubo

Confirmation No.:

8003

For:

NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING

TO STREPTOCOCCUS PNEUMONIAE FOR DIAGNOSTICS

AND THERAPEUTICS

CERTIFICATE OF MAILING OR TRANSMISSION I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 223.13-1450, or is being facsimile transmitted to the United States Patent and Traffemark Office on: | Date | Separature | Commissioner for Patents | Date | Separature | Commissioner for Patents | Date | Commissioner for Patents | Date | Date | Commissioner for Patents | Date | Da

REQUEST FOR CHANGE OF DOCKET NUMBER AND CORRECTED FILING RECEIPT

Customer Correction Office Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants' Attorney requests that the docket number of record for the above-referenced case be changed to 3687.1000-004. This request is made to better identify this application within our offices.

In addition, please correct the Filing Receipt to include the following corrections:

Under "Domestic Priority data as claimed by applicant," please change "This application is a DIV of 09/107,433" to "This application is a CON of 09/107,433".

10/617,320 -2-

A copy of a Second Preliminary Amendment requesting an amendment to the specification to correct the priority information is being filed concurrently herewith and is attached to this request.

Further, please correct the Filing Receipt to include the Customer Number and Correspondence Address as filed in the Revocation of Powers of Attorney and Appointment of New Attorneys and/or Agents and Change of Correspondence Address on June 22, 2004, a copy of which is attached.

Enclosed are copies of the Filing Receipt with changes noted in red.

Pursuant to instructions in the February 29, 2000 O.G., we hereby request that the errors which are identified above be corrected in the captioned application to which this request for correction is directed. Please provide a corrected Filing Receipt indicating the new attorney docket number, corrected priority information and change of correspondence and new customer number. It is understood that the Patent Office will issue an automatically-generated, corrected Filing Receipt in this and, if applicable, any other affected applications.

Please charge Deposit Account No. 08-0380 for any fees that may be due in this matter. One additional copy of this document is enclosed for accounting purposes.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

Munay


Mary K. Murray

Registration No. 47,813

Telephone: (978) 341-0036 Facsimile: (978) 341-0136

Concord, MA 01742-9133

Date: December 9, 2004



021005

Robert L. Spadafora Hamilton, Brook, Smith & Reynolds, P.C.

Waltham, MA-02453

Genome Therapeutics Gerporation 530 virgin ia Road
100 Beaver Street
P.O. Box 9/33

Concord, massachusetts 01742-9133

CONFIRMATION NO. 8003

UPDATED FILING RECEIPT

Date Mailed: 05/26/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Lynn A. Doucette-Stamm, Framingham, MA; David Bush, Somerville, MA;

Domestic Priority data as claimed by applicant

This application is a DIV of 09/107,433 06/30/1998 which claims benefit of 60/051,553 07/02/1997 and claims benefit of 60/085,131 05/12/1998

Foreign Applications

If Required, Foreign Filing License Granted: 11/07/2003

Projected Publication Date: 09/02/2004

Non-Publication Request: No

Early Publication Request: No

Title

Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PATENT APPLICATION Attorney's Docket No.: 3687.1000-004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Lynn A. Doucette-Stamm and David Bush

Application No.:

10/617,320

Filed:

July 10, 200

Confirmation No.:

8003

Examiner: Zhou, Shubo

1631

For:

NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO

Group:

STREPTOCOCCUS PNEUMONIAE FOR DIAGNOSTICS AND

THERAPEUTICS

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent

and Trademark Office on: 04

Date

Signature

Typed or printed name of person signing certificate

SECOND PRELIMINARY AMENDMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Please amend the application as follows:

Amendments to the Specification

Please replace the paragraph at page 1, line 5 with the following amended paragraph:

This application is a continuation a divisional of U.S. Application No.: 09/107,433, filed June 30, 1998, which claims priority of U.S. provisional applications 60/051,553, filed July 2, 1997; and 60/085131 60/085,131 filed May 12, 1998, all of which are hereby incorporated herein by reference in their entirety.

REMARKS

The amendment to the specification is made to correctly identify the above-referenced application as a continuation application of U.S. Application No. 09/107,433, filed June 30, 1998, to which the above-referenced application claims priority. No new matter has been added. Entry is respectfully requested.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

Mary K. Murray

Registration No.: 47,813 Telephone: (978) 341-0036 Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:

December 9, 2004



Applicants:

Lynn A. Doucette-Stamm and David Bush

Application No.:

10/617.320

Group Art Unit:

1645

Filed:

July 10, 2003 ·

Examiner:

Not Yet Assigned

Confirmation No.:

8003

Title:

NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO

STREPTOCOCCUS PNEUMONIAE FOR DIAGNOSTICS AND

THERAPEUTICS

CERTIFICATE OF MAILING OR TRANSMISSION

I heroby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facting ite transmitted to the United States Patent

and Trademark Office on:

Signature

Typed or printed name of person signing certificate

REVOCATION OF POWERS OF ATTORNEY AND APPOINTMENT OF NEW ATTORNEYS AND/OR AGENTS AND CHANGE OF CORRESPONDENCE ADDRESS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Aventis Pasteur Ltd., a Corporation duly organized under the laws of Ontario, Canada, is the assignee of the entire right, title and interest in the above-identified application. Aventis Pasteur Ltd. hereby appoints the attorneys and/or agents associated with:

Customer No. 021005

Hamilton, Brook, Smith & Reynolds, P.C.

530 Virginia Road

P.O. Box 9133

Concord, Massachusetts 01742-9133

BEST AVAILABLE COPY



to prosecute the above-identified application and any divisions or continuations thereof and to conduct all business in the United States Patent and Trademark Office. All previously granted Powers of Attorney are hereby revoked.

A Statement under 37 C.F.R. §3.73(b) is submitted herewith.


All correspondence should be sent to Customer No. 021005, Hamilton, Brook, Smith & Reynolds, P.C., 530 Virginia Road, P.O. Box 9133, Concord, Massachusetts 01742-9133. Please direct all telephone calls to Doreen M. Hogle at (978) 341-0036, and all facsimile communications to (978) 341-0136.

> Respectfully submitted, AVENTIS PASTEUR LTD.

Title Corp. V.P. - Intellectual Property

Date 17 Jan 2004





TRANSPORTEMENT UNDER 37 C.F.R. § 3.73(b)

hine	ation No./	Patent No.:	10/617,320	Filed/Issue Date:	July 10, 2003	
For:	Nucleic	Acid and Amino	Acid Sequences Re	elating to Streptococcus Pneumoniae	for Diagnostics and Thera	oeutics_
	Aventis	Pasteur Ltd. (Name of Assignee)		, a <u>Corporation</u> (Type of Assignee, e.g., corporation	s, partnership, university, government	agency, etc.)
states t	hat it is	(
A.	[X]	the assignee of	the entire right, title	and interest in the patent application	identified above; or	
В.	[]	an assignee tog	ether with [] of the entire right, title and interest	in the patent application i	dentified
The rig	tht, title a	nd interest of the	above-named assign	ee in the patent application identified	above is established by v	irtue of:
A. []	An assi and Tra	gnment from the demark Office at	inventor(s) of the part Reel	ttent application identified above. Th	e assignment was recorded by thereof is attached.	d in the Pa
OR		•		·		
в, [Х] A chair	of title from the	inventor(s) of the p	atent application identified above, to t	the current assignee as sho	wn below:
	i.	The document	was recorded in the	nd David Bush To: Genome Theran United States Patent and Trademark (899 , or a copy thereof is attached	Office at	
	2.	From: Genor	was recorded in the	poration To: <u>Aventis Pasteur Lt</u> United States Patent and Trademark (, or a copy thereof is attache	Office at	
		Reel	, 1100110		-	
	3. .	From: The document	was recorded in the	To: United States Patent and Trademark (, or a copy thereof is attached.	·	
		From: The document Reel	was recorded in the, Frame	_To:	·	
The ur	[] Ac	From: The document Reel Iditional docume	was recorded in the, Frame ints in the chain of ti	To: United States Patent and Trademark (, or a copy thereof is attached.	Office at	
The un	[] Ac	From: The document Reel Iditional docume I (whose title is s	was recorded in the, Frame ints in the chain of ti upplied below) is au	To: United States Patent and Trademark (, or a copy thereof is attached. tle are listed on a supplemental sheet.	Office at	
The un Date:_ Name: Title:_ Signat	[] Addersigned 17 J John Carp J	From: The document Reel Iditional docume I (whose title is s I LUY E Parri	was recorded in the, Frame ints in the chain of ti upplied below) is au	To: United States Patent and Trademark (, or a copy thereof is attached. tle are listed on a supplemental sheet. thorized to act on behalf of the assign	Office at	

BEST AVAILABLE COPY

ASSIGNMENT

WHEREAS, by virtue of Assignments recorded in the United States Patent and Trademark Office, Genome Therapeutics Corporation ("ASSIGNOR") of 100 Beaver Street, Waltham, Massachusetts 02453, is the owner of certain patent applications as follows:

Application No.	Filing Date	Reel/Frames
60/051,553	July 2, 1997	010210/0822-0828
60/085,131	May 12, 1998	010210/0480-0487
09/107,433	June 30, 1998	010210/0892-0899
09/583,110	May 26, 2000	011422/0548-0554
10/617,320	July 10, 2003	
10/640,833	August 14, 2003.	

WHEREAS, Aventis Pasteur Ltd ("ASSIGNEE"), of 1755 Steeles Avenue West, Toronto, Ontario, Canada M2R 3T4, is desirous of acquiring from Genome Therapeutics Corporation an ownership right, title and interest in, to and under the Patent Application's listed on the Attachment, and the inventions therein described and claimed.

NOW; therefore, for good and valuable consideration, the receipt of which is hereby acknowledged, Genome Therapeutics Corporation hereby sells, transfers and conveys its ownership right, title and interest in, to and under said Parent Applications referenced he rein and the invention therein described and claimed to Aventis Pasteur Ltd to the full end of the term for which Letters Patent may be granted and hereby authorizes and requests the Commissioner of Patents and Trademarks to issue said Letters Patent when granted to Aventis Pasteur Ltd as the assignee of an ownership right, title and interest in, to and under the same.

ASSIGNOR further agrees that Assignor will, without demanding any further consideration therefor, at the request but at the expense of Assignee, do all lawful and just acts, including the execution and acknowledgment of instruments, that may be or become necessary for obtaining, sustaining, or reissuing said Letters Patent as may be granted from said Patent Application, and for maintaining and perfecting Assignee's right to said Letters Patent.

Genome Therapeutics Corporation

Date

BEST AVAILABLE COPY



State/Commons	wealth of C	955011118 2 TU	 .		
County of/	<u> Middlese</u>	<u> </u>			
acknowledged to on behalf of suc	hat he is an offic:	me the above-named er of said corporation, th authority to do so, a ion.	that he exec	uted the foregoin	ig instrument
Dated this	24H	day of April	44.0	, 20 <u>/)4</u> .	
(SEAL)		Carolyn A. G. My Commission	<u> </u>	(print name)	

@PFDesktopv:ODMA/MHODMA/HBSR05;(Manape:453932;)